Α-Melanocyte-stimulating hormone (Α-MSH1-13), a peptide derived from proopiomelanocortin, has remarkable anti-inflammatory and antipyretic activities. This peptide and a tripeptide that forms the COOH-terminal portion of the molecule (Α-MSH11-13; Lys Pro Val) inhibit inflammation when given centrally or peripherally Because of the similarity in their actions, the tripeptide has been presumed to be the amino acid message sequence underlying the effects ofΑ-MSH1-13. To test the possibility that the two peptides occupy the same receptors, competitive binding experiments were performed with B16 mouse melanoma cells that are known to haveΑ-MSH1-13receptors. In these experiments,Α-MSH1-13did not inhibit binding of a radiolabelledΑ-MSH1-13analog. This finding suggests thatΑ-MSH1-13andΑ-MSH11-13exert their anti-inflammatory/antipyretic/anticytokine effects via stimulation of separate receptors. BecauseΑ-MSH inhibits the effects of several cytokines including inflammation caused by interleukin (IL)-6 and IL-8, the capacity of these cytokines to compete forΑ-MSH binding sites was tested. There was no evidence that these proinflammatory cytokines bind toΑ-MSH receptors on murine melanoma cells. Although further tests with host cells involved in inflammation are required, the latter result is the first evidence that the mechanism of anticytokine action ofΑ-MSH does not depend upon peptide/cytokine competition for binding sites.

Keywords:
α-MSH1-13receptors, α-MSH11-13receptors, Melanocytes, α-MSH analog, Saturation binding, Competitive binding, Interleukin-6, Interleukin-8
This content is only available via PDF.
© 1994 S. Karger AG, Basel
1994
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.